ArticleBMJ open2021

Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes.

Charlotte S Wilhelm-Benartzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.